Clinical Trial TitlePhase III trial of docetaxel vs. docetaxel and radium-223 for metastatic castration-resistant prostate cancer (mCRPC).
Clinical Trial Protocol Description:
This is an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in subjects with mCRPC.
Clinical Trial Eligibility Criteria:
In order to participate you must have:
- Have histological or cytological proof of prostate cancer.
- Have received external beam radiotherapy within the 4 weeks prior to randomization.
- Have received four or more systemic anticancer regimens for mCRPC.
This is a partial list of inclusion and exclusion criteria.